PL4269444T3 - Wieloswoiste przeciwciała anty-tcr zmienne delta 1 - Google Patents

Wieloswoiste przeciwciała anty-tcr zmienne delta 1

Info

Publication number: PL4269444T3
Authority: PL; Poland
Prior art keywords: tcr antibodies; multispecific anti; variable delta; antibodies variable; delta
Prior art date: 2020-08-14

Application number

PL23187269.8T

Other languages

English (en)

Inventor

Mark Uden

Mihriban Tuna

Natalie MOUNT

Robert Good

Joshua Freedman

Shefali BHUMBRA

Oliver Nussbaumer

Raj Jaysukhlal MEHTA

Original Assignee

GammaDelta Therapeutics Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-08-14

Filing date

2021-08-14

Publication date

2025-01-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80247426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4269444(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2020-08-14 Priority claimed from PCT/GB2020/051959 external-priority patent/WO2021032963A1/en

2021-02-17 Priority claimed from GBGB2102224.9A external-priority patent/GB202102224D0/en

2021-02-17 Priority claimed from GBGB2102222.3A external-priority patent/GB202102222D0/en

2021-08-14 Application filed by GammaDelta Therapeutics Limited filed Critical GammaDelta Therapeutics Limited

2025-01-13 Publication of PL4269444T3 publication Critical patent/PL4269444T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Oncology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Steroid Compounds (AREA)

PL23187269.8T 2020-08-14 2021-08-14 Wieloswoiste przeciwciała anty-tcr zmienne delta 1 PL4269444T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/GB2020/051959 WO2021032963A1 (en)	2019-08-16	2020-08-14	Therapeutic uses of anti-tcr delta variable 1 antibodies
GBGB2102224.9A GB202102224D0 (en)	2021-02-17	2021-02-17	Anti-TRC delta variable 1 antibodies
GBGB2102222.3A GB202102222D0 (en)	2021-02-17	2021-02-17	Multispecific anti-TCR delta variable 1 antibodies

Publications (1)

Publication Number	Publication Date
PL4269444T3 true PL4269444T3 (pl)	2025-01-13

Family

ID=80247426

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL23187269.8T PL4269444T3 (pl)	2020-08-14	2021-08-14	Wieloswoiste przeciwciała anty-tcr zmienne delta 1
PL21756070.5T PL4010082T5 (pl)	2020-08-14	2021-08-14	Wieloswoiste przeciwciała anty-tcr zmienne delta 1

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL21756070.5T PL4010082T5 (pl)	2020-08-14	2021-08-14	Wieloswoiste przeciwciała anty-tcr zmienne delta 1

Country Status (18)

Country	Link
EP (7)	EP4269446B1 (pl)
JP (1)	JP7847579B2 (pl)
KR (1)	KR20230083267A (pl)
CN (1)	CN116209456A (pl)
AU (1)	AU2021323512A1 (pl)
BR (1)	BR112023002741A2 (pl)
CA (1)	CA3188682A1 (pl)
CO (1)	CO2023003009A2 (pl)
DK (2)	DK4269444T5 (pl)
ES (2)	ES2943063T5 (pl)
FI (2)	FI4269444T3 (pl)
IL (1)	IL300517A (pl)
LT (2)	LT4269444T (pl)
MX (1)	MX2023001728A (pl)
PL (2)	PL4269444T3 (pl)
PT (2)	PT4010082T (pl)
SI (2)	SI4010082T1 (pl)
WO (1)	WO2022034562A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP7847579B2 (ja)	2020-08-14	2026-04-17	ガンマデルタセラピューティクスリミテッド	多特異性抗ｔｃｒデルタ可変１抗体
JP2025519645A (ja) *	2022-06-23	2025-06-26	ラヴァ・セラピューティクス・エヌ・ヴイ	Ｔ細胞依存性多重特異性化合物のアッセイ
EP4680729A1 (en) *	2023-03-17	2026-01-21	Legend Biotech Ireland Limited	Methods of culturing v delta 1 t cells
WO2025147597A1 (en) *	2024-01-05	2025-07-10	Eugit Therapeutics, Inc.	Targeting payloads
WO2025191133A1 (en)	2024-03-15	2025-09-18	Avidicure Ip B.V.	Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en)	2024-03-15	2025-09-18	Avidicure Ip B.V.	Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2026087747A1 (en)	2024-10-24	2026-04-30	Avidicure Ip B.V.	Multispecific antigen binding proteins for tumor-targeting of γδ1 t cells and use thereof
WO2026087748A1 (en)	2024-10-24	2026-04-30	Avidicure Ip B.V.	Multispecific antigen binding proteins for the expansion of γδ t cells and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2546268A1 (en)	2011-07-13	2013-01-16	F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H.	Internalising immunoglobulin
WO2015063069A1 (en) *	2013-10-28	2015-05-07	Benjamin Felder	Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
GB201506423D0 (en) *	2015-04-15	2015-05-27	Tc Biopharm Ltd	Gamma delta T cells and uses thereof
US11166983B2 (en)	2015-06-09	2021-11-09	Lymphact—Lymphocyte Activation Technologies, S.A.	Methods for the production of TCRγδ+ T cells
EP3344658B1 (en) *	2015-09-02	2022-05-11	Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.	Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
CA3003077A1 (en)	2015-10-30	2017-05-04	King's College London	Expansion of non-haematopoietic tissue-resident .gamma.delta. t cells and uses of these cells
MX2018013864A (es)	2016-05-12	2019-06-10	Adicet Bio Inc	Métodos para la expansión selectiva de poblaciones de células t gama y composicicones de estas.
GB201612520D0 (en)	2016-07-19	2016-08-31	F-Star Beta Ltd	Binding molecules
US20180028566A1 (en)	2016-07-29	2018-02-01	New York University	Gamma delta t cells as a target for treatment of solid tumors
US10546518B2 (en)	2017-05-15	2020-01-28	Google Llc	Near-eye display with extended effective eyebox via eye tracking
WO2019005637A2 (en)	2017-06-25	2019-01-03	Systimmune, Inc.	MULTIPECIFIC ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF
EP3743081A4 (en)	2018-01-23	2021-12-01	New York University	SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR
BR112021005184A8 (pt) *	2018-09-19	2022-08-16	Lava Therapeutics B V	Imunoglobulina cd1d de dupla ação
GB201818243D0 (en)	2018-11-08	2018-12-26	Gammadelta Therapeutics Ltd	Methods for isolating and expanding cells
CN114144190B (zh) *	2019-01-23	2025-08-08	纽约大学	对T细胞受体的δ1链具有特异性的抗体
EP3917960A1 (en) *	2019-02-01	2021-12-08	LAVA Therapeutics N.V.	Novel cd40-binding antibodies
KR20220006065A (ko)	2019-04-08	2022-01-14	메모리얼 슬로안 케터링 캔서 센터	Cd19 항체 및 이의 사용 방법
EP4013787A1 (en)	2019-08-16	2022-06-22	GammaDelta Therapeutics Limited	Ex vivo gamma delta t cell populations
CA3145517A1 (en)	2019-08-16	2021-02-25	GammaDelta Therapeutics Limited	Novel anti-tcr delta variable 1 antibodies
JP7847579B2 (ja)	2020-08-14	2026-04-17	ガンマデルタセラピューティクスリミテッド	多特異性抗ｔｃｒデルタ可変１抗体
KR20230160253A (ko)	2021-02-17	2023-11-23	감마델타 테라퓨틱스 엘티디	항-tcr 델타 가변 1 항체

2021
- 2021-08-14 JP JP2023510439A patent/JP7847579B2/ja active Active
- 2021-08-14 EP EP23187273.0A patent/EP4269446B1/en active Active
- 2021-08-14 SI SI202130032T patent/SI4010082T1/sl unknown
- 2021-08-14 CN CN202180069269.3A patent/CN116209456A/zh active Pending
- 2021-08-14 FI FIEP23187269.8T patent/FI4269444T3/fi active
- 2021-08-14 MX MX2023001728A patent/MX2023001728A/es unknown
- 2021-08-14 DK DK23187269.8T patent/DK4269444T5/da active
- 2021-08-14 IL IL300517A patent/IL300517A/en unknown
- 2021-08-14 KR KR1020237005145A patent/KR20230083267A/ko active Pending
- 2021-08-14 PT PT217560705T patent/PT4010082T/pt unknown
- 2021-08-14 FI FIEP21756070.5T patent/FI4010082T4/fi active
- 2021-08-14 ES ES21756070T patent/ES2943063T5/es active Active
- 2021-08-14 EP EP21756070.5A patent/EP4010082B9/en active Active
- 2021-08-14 EP EP23187269.8A patent/EP4269444B1/en active Active
- 2021-08-14 SI SI202130192T patent/SI4269444T1/sl unknown
- 2021-08-14 PT PT231872698T patent/PT4269444T/pt unknown
- 2021-08-14 BR BR112023002741A patent/BR112023002741A2/pt unknown
- 2021-08-14 AU AU2021323512A patent/AU2021323512A1/en active Pending
- 2021-08-14 EP EP23187271.4A patent/EP4265643B1/en active Active
- 2021-08-14 CA CA3188682A patent/CA3188682A1/en active Pending
- 2021-08-14 PL PL23187269.8T patent/PL4269444T3/pl unknown
- 2021-08-14 PL PL21756070.5T patent/PL4010082T5/pl unknown
- 2021-08-14 ES ES23187269T patent/ES2993071T3/es active Active
- 2021-08-14 WO PCT/IB2021/057509 patent/WO2022034562A1/en not_active Ceased
- 2021-08-14 LT LTEP23187269.8T patent/LT4269444T/lt unknown
- 2021-08-14 DK DK21756070.5T patent/DK4010082T4/da active
- 2021-08-14 EP EP23187272.2A patent/EP4269445B1/en active Active
- 2021-08-14 LT LTEPPCT/IB2021/057509T patent/LT4010082T/lt unknown
- 2021-08-14 EP EP23153152.6A patent/EP4218932A3/en active Pending
- 2021-08-14 EP EP23187270.6A patent/EP4265642B1/en active Active
2023
- 2023-03-13 CO CONC2023/0003009A patent/CO2023003009A2/es unknown

Also Published As

Publication number	Publication date
EP4265643A3 (en)	2024-02-14
PT4010082T (pt)	2023-04-26
JP7847579B2 (ja)	2026-04-17
EP4010082B1 (en)	2023-01-25
CN116209456A (zh)	2023-06-02
EP4265642A2 (en)	2023-10-25
LT4269444T (lt)	2024-09-25
ES2993071T3 (en)	2024-12-20
ES2943063T3 (es)	2023-06-08
EP4269446B1 (en)	2024-06-26
DK4269444T5 (da)	2024-08-26
DK4269444T3 (en)	2024-08-19
SI4269444T1 (sl)	2024-10-30
EP4218932A2 (en)	2023-08-02
LT4010082T (lt)	2023-03-10
EP4269444A2 (en)	2023-11-01
CO2023003009A2 (es)	2023-03-17
PT4269444T (pt)	2024-09-05
CA3188682A1 (en)	2022-02-17
DK4010082T4 (en)	2026-02-16
EP4269446A3 (en)	2024-02-14
EP4269445A2 (en)	2023-11-01
WO2022034562A1 (en)	2022-02-17
SI4010082T1 (sl)	2023-04-28
MX2023001728A (es)	2023-04-20
EP4269444B1 (en)	2024-06-26
AU2021323512A1 (en)	2023-04-13
EP4010082B2 (en)	2025-12-31
FI4269444T3 (fi)	2024-09-20
EP4265643B1 (en)	2024-06-26
IL300517A (en)	2023-04-01
PL4010082T5 (pl)	2026-03-09
FI4010082T4 (fi)	2026-03-24
EP4010082B9 (en)	2026-03-04
EP4265643A2 (en)	2023-10-25
EP4269446A2 (en)	2023-11-01
EP4265642A3 (en)	2024-02-14
DK4010082T3 (da)	2023-04-03
EP4269444A3 (en)	2024-02-14
JP2023537534A (ja)	2023-09-01
EP4218932A3 (en)	2023-09-27
PL4010082T3 (pl)	2023-05-29
BR112023002741A2 (pt)	2023-10-10
EP4269445B1 (en)	2024-06-26
FI4010082T3 (fi)	2023-04-04
DK4010082T5 (da)	2024-08-05
EP4265642B1 (en)	2024-06-26
ES2943063T5 (en)	2026-05-05
KR20230083267A (ko)	2023-06-09
EP4269445A3 (en)	2024-02-14
EP4010082A1 (en)	2022-06-15

Publication	Publication Date	Title
IL290537A (en)	2022-04-01	Therapeutic uses of anti-tcr delta variable 1 antibodies
DK4269444T3 (en)	2024-08-19	Multispecific anti-tcr delta variable 1 antibodies
CR20230573A (es)	2024-05-07	ANTICUERPOS ANTI-SIRP-alfa
DK4214240T3 (da)	2024-11-18	Anti-ccr8-antistoffer
IL311043A (en)	2024-04-01	Anti-il-11rα antibodies
IL310245A (en)	2024-03-01	Anti-hla-g antibodies
JP1739620S (ja)	2023-03-22	ベンチ
EP4392455A4 (en)	2025-08-20	ANTI-CD-25 ANTIBODIES
ZA202308120B (en)	2024-12-18	Multispecific anti-tcr delta variable 1 antibodies
DK4172199T3 (da)	2025-08-18	Alfa-synuklein-protofibril-bindende antistoffer
EP4431606A4 (en)	2025-11-26	ANTI-EPHA4 ANTIBODIES
EP4323408A4 (en)	2025-08-27	NEW ANTI-HVEGFR2 ANTIBODIES
GB202111685D0 (en)	2021-09-29	Anti-tcr delta variable 1 antibodies
EP4311082A4 (en)	2024-11-27	COMPONENT
GB202102222D0 (en)	2021-03-31	Multispecific anti-TCR delta variable 1 antibodies
ES1255385Y (es)	2021-01-20	Bandeja
HK40104958A (en)	2024-08-02	Multispecific anti-tcr delta variable 1 antibodies
EP4743115A2 (en)	2026-05-20	MULTISPECIFIC ANTIBODIES AND THEIR USES
EP4342989A4 (en)	2024-09-25	ANTI-NOROVIRUS ANTIBODIES
EP4419567A4 (en)	2025-09-17	MULTI-SPECIFIC ANTI-TSHR ANTIBODIES AND THEIR USES
EP4453327C0 (de)	2025-11-26	Schnellwechsler
JP1761937S (ja)	2024-01-22	ノート
EP4471096A4 (en)	2026-01-21	MOLDED ITEM
EP4519356A4 (en)	2026-03-11	MOLDED ITEM
CA210250S (fr)	2023-05-04	Balance